BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 28844122)

  • 1. Clinical significance of radiation-induced liver disease after stereotactic body radiation therapy for hepatocellular carcinoma.
    Jun BG; Kim YD; Cheon GJ; Kim ES; Jwa E; Kim SG; Kim YS; Kim BS; Jeong SW; Jang JY; Lee SH; Kim HS
    Korean J Intern Med; 2018 Nov; 33(6):1093-1102. PubMed ID: 28844122
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Radiation-induced liver disease after stereotactic body radiotherapy for small hepatocellular carcinoma: clinical and dose-volumetric parameters.
    Jung J; Yoon SM; Kim SY; Cho B; Park JH; Kim SS; Song SY; Lee SW; Ahn SD; Choi EK; Kim JH
    Radiat Oncol; 2013 Oct; 8():249. PubMed ID: 24160910
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biologically effective dose (BED) of stereotactic body radiation therapy (SBRT) was an important factor of therapeutic efficacy in patients with hepatocellular carcinoma (≤5 cm).
    Sun J; Zhang T; Wang J; Li W; Zhang A; He W; Zhang D; Li D; Ding J; Duan X
    BMC Cancer; 2019 Aug; 19(1):846. PubMed ID: 31455251
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dosimetric analysis and comparison of three-dimensional conformal radiotherapy and intensity-modulated radiation therapy for patients with hepatocellular carcinoma and radiation-induced liver disease.
    Cheng JC; Wu JK; Huang CM; Liu HS; Huang DY; Tsai SY; Cheng SH; Jian JJ; Huang AT
    Int J Radiat Oncol Biol Phys; 2003 May; 56(1):229-34. PubMed ID: 12694843
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A mouse radiation-induced liver disease model for stereotactic body radiation therapy validated in patients with hepatocellular carcinoma.
    Wu ZF; Zhang JY; Shen XY; Zhou LY; Gao YB; Hu Y; Zeng ZC
    Med Phys; 2016 Jul; 43(7):4349. PubMed ID: 27370150
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predictors of Liver Toxicity Following Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma.
    Velec M; Haddad CR; Craig T; Wang L; Lindsay P; Brierley J; Brade A; Ringash J; Wong R; Kim J; Dawson LA
    Int J Radiat Oncol Biol Phys; 2017 Apr; 97(5):939-946. PubMed ID: 28333016
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Metabolic liver function after stereotactic body radiation therapy for hepatocellular carcinoma.
    Dreher C; Høyer KI; Fode MM; Habermehl D; Combs SE; Høyer M
    Acta Oncol; 2016 Jul; 55(7):886-91. PubMed ID: 26878669
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Estimation of the risk for radiation-induced liver disease following photon- or proton-beam radiosurgery of liver metastases.
    Mondlane G; Ureba A; Gubanski M; Lind PA; Siegbahn A
    Radiat Oncol; 2018 Oct; 13(1):206. PubMed ID: 30348194
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and Efficacy of Accelerated Hypofractionation and Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma Patients With Varying Degrees of Hepatic Impairment.
    Nabavizadeh N; Waller JG; Fain R; Chen Y; Degnin CR; Elliott DA; Mullins BT; Patel IA; Dyer BA; Fakhoury K; Naugler WE; Farsad K; Tanyi JA; Fuss M; Thomas CR; Hung AY
    Int J Radiat Oncol Biol Phys; 2018 Mar; 100(3):577-585. PubMed ID: 29413273
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical Values and Markers of Radiation-Induced Liver Disease for Hepatocellular Carcinoma With Portal Vein Tumor Thrombus Treated With Stereotactic Body Radiotherapy.
    Jia J; Sun J; Duan X; Li W
    Front Oncol; 2021; 11():760090. PubMed ID: 34970485
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapeutic outcome and related predictors of stereotactic body radiotherapy for small liver-confined HCC: a systematic review and meta-analysis of observational studies.
    Long Y; Liang Y; Li S; Guo J; Wang Y; Luo Y; Wu Y
    Radiat Oncol; 2021 Apr; 16(1):68. PubMed ID: 33832536
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dosimetric analysis of liver toxicity after liver metastasis stereotactic body radiation therapy.
    Barry A; McPartlin A; Lindsay P; Wang L; Brierley J; Kim J; Ringash J; Wong R; Dinniwell R; Craig T; Dawson LA
    Pract Radiat Oncol; 2017; 7(5):e331-e337. PubMed ID: 28442242
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predictors of Radiation-Induced Liver Disease in Eastern and Western Patients With Hepatocellular Carcinoma Undergoing Proton Beam Therapy.
    Hsieh CE; Venkatesulu BP; Lee CH; Hung SP; Wong PF; Aithala SP; Kim BK; Rao A; Tung-Chieh Chang J; Tsang NM; Wang CC; Lee CC; Lin CC; Tseng JH; Chou WC; Wang YC; Krishnan S; Hong JH
    Int J Radiat Oncol Biol Phys; 2019 Sep; 105(1):73-86. PubMed ID: 30797890
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessment of hepatic function decline after stereotactic body radiation therapy for primary liver cancer.
    Toesca DAS; Osmundson EC; von Eyben R; Shaffer JL; Koong AC; Chang DT
    Pract Radiat Oncol; 2017; 7(3):173-182. PubMed ID: 28343896
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Stereotactic body radiation therapy (SBRT) for definitive treatment and as a bridge to liver transplantation in early stage inoperable Hepatocellular carcinoma.
    Moore A; Cohen-Naftaly M; Tobar A; Kundel Y; Benjaminov O; Braun M; Issachar A; Mor E; Sarfaty M; Bragilovski D; Hur RB; Gordon N; Stemmer SM; Allen AM
    Radiat Oncol; 2017 Oct; 12(1):163. PubMed ID: 29052532
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Baseline Albumin-Bilirubin (ALBI) Score in Western Patients With Hepatocellular Carcinoma Treated With Stereotactic Body Radiation Therapy (SBRT).
    Murray LJ; Sykes J; Brierley J; Kim JJ; Wong RKS; Ringash J; Craig T; Velec M; Lindsay P; Knox JJ; Dawson LA
    Int J Radiat Oncol Biol Phys; 2018 Jul; 101(4):900-909. PubMed ID: 29976502
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Early radiation-induced liver toxicities are associated with poor survival in patients with advanced hepatocellular carcinoma.
    Lai YL; Kuo YC; Lai HC; Peng CY; Wang YC; Liang JA; Chen SW
    Asia Pac J Clin Oncol; 2016 Dec; 12(4):437-443. PubMed ID: 26947774
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The significance of ICG-R15 in predicting hepatic toxicity in patients receiving radiotherapy for hepatocellular carcinoma.
    Yoon HI; Koom WS; Lee IJ; Jeong K; Chung Y; Kim JK; Lee KS; Han KH; Seong J
    Liver Int; 2012 Aug; 32(7):1165-71. PubMed ID: 22435801
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Radiation-induced liver disease after three-dimensional conformal radiotherapy for patients with hepatocellular carcinoma: dosimetric analysis and implication.
    Cheng JC; Wu JK; Huang CM; Liu HS; Huang DY; Cheng SH; Tsai SY; Jian JJ; Lin YM; Cheng TI; Horng CF; Huang AT
    Int J Radiat Oncol Biol Phys; 2002 Sep; 54(1):156-62. PubMed ID: 12182986
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment Outcome after Fractionated Conformal Radiotherapy for Hepatocellular Carcinoma in Patients with Child-Pugh Classification B in Korea (KROG 16-05).
    Bae SH; Park HC; Yoon WS; Yoon SM; Jung IH; Lee IJ; Kim JW; Seong J; Kim TH; Nam TK; Choi Y; Lee SY; Jang HS; Lee DS; Kim JH
    Cancer Res Treat; 2019 Oct; 51(4):1589-1599. PubMed ID: 30971065
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.